News and Trends 5 Dec 2018 Llama-Inspired Antibodies Succeed in Clinical Trials and Financial Deal Autoimmune disease and acute myeloid leukemia may have a llama-inspired antibody treatment one day. The Dutch company argenx’s antibodies have shown positive results in clinical trials, and have attracted Janssen… December 5, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2017 An Antibody to reduce Hospitalizations of Children starts Phase IIb trials …JP Morgan this year, develops nanobodies derived from llamas. The Belgian company announced yesterday that its candidate ALX-0171 has entered testing in Phase IIb as a treatment for respiratory syncytial… January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2016 Shooting for the Moon: German Biotech Acquired for a Record €1.3B …in Germany. Astellas will pay €442M upfront and is offering up to an extra €860M pending the successful development of Ganymed’s pipeline lead candidate, IMAB362. The therapeutic antibody has orphan… October 31, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 15 May 2024 Drugs for IgA nephropathy on the rise in the clinic …the kidneys against placebo in a phase 3 trial. The study is set to end next year. Moreover, Boston-based Alexion Pharmaceuticals’ monoclonal antibody ALXN1210, also known as ravulizumab is currently… May 15, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2019 Swiss-Italian Biotech Bags Antibody Deals with Three Big Pharma The Swiss-Italian company Philogen has announced three different partnerships with Novartis, Celgene, and Janssen to develop new forms of immunotherapy and small molecule drugs. Philogen develops immunocytokines, which are antibodies… January 25, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Mar 2022 €80M Series B Establishes European Champion in Radiopharmaceuticals …cancer-seeking component is a fragment of an antibody found in animals from the camelid family, which includes llamas and camels. These antibody fragments bind to their targets as strongly as… March 17, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 2 Sep 2020 An Alzheimer’s Vaccine Challenged the Consensus for 25 Years …proteins interact with each other, forming aggregates. The team at Axon was able to identify it by developing an antibody that blocked the interaction between tau proteins by targeting that… September 2, 2020 - 8 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
Best in Biotech 9 May 2023 5 cancers that immunotherapy can cure …for multiple myeloma.The first three approved immunotherapies for multiple myeloma were antibody-based immunotherapies, all approved for subsets of patients with advanced multiple myeloma: daratumumab (Darzalex) – a monoclonal antibody targeting… May 9, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2017 Update: Danish Psoriasis Drug Gets EU Approval Despite Suicide Links …a positive opinion for Leo Pharma’s psoriasis drug brodalumab, even though the drug has been associated with suicidal behavior. Brodalumab, a fully human antibody targeting the IL-17 receptor, is part… July 20, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 19 Feb 2018 Is Novartis’ Psoriasis Drug Going to Steal Humira’s Crown? Two clinical studies have demonstrated the capacity of Novartis’ monoclonal antibody to treat both plaque and scalp psoriasis and improve patient quality of life. Not only is Novartis leading the… February 19, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 2 Jan 2017 The Story behind one of the Most Successful Danish Biotech Entrepreneurs …became co-founders of Symphogen. I was in my 30s and we believed everything was possible, including building the next big antibody company; an idea inspired by Genmab, now a €10Bn… January 2, 2017 - 6 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jun 2017 Understand your Biologics: De-Risking the Biotech Pipeline …of the top-selling drugs worldwide are antibodies and recombinant proteins, and new technologies such as Antibody-Drug Conjugates (ADCs) are on track to revolutionize the extremely challenging oncology field. However, since… June 14, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email